Thanks, sure would be nice to hit that target soon after plunging from #2.50 to pennyland overnight end of June, with still no explanation for how PH III could have led down such a blind alley:
Out of the 7 analysts polled by TipRanks, 5 rate Galena stock a Buy, while 2 rate the stock a Hold. With a return potential of 681%, the stock’s consensus target price stands at $2.34.
Short-term we're looking at a split that's gotta be a minimum of 4:1 now by the time the "vote" comes in 10 days, they have no choice if they want to stay on NASDAQ. Worst performing stock on the Big Boards last year, can only go UP.
I'm really hoping for a buyout from Roche!
